FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US
Go back to FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US| Amgen Inc (NASDAQ: AMGN) | Delayed: 401.05 +7.89 (2.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $393.16 | 52 Week High | $176.85 | |||
| Open | $405.25 | 52 Week Low | $133.64 | |||
| Day High | $407.00 | P/E | 60.40 | |||
| Day Low | $398.52 | EPS | $6.64 | |||
| Volume | 961,031 | |||||
